Please use this identifier to cite or link to this item:
http://ri.uaemex.mx/handle20.500.11799/105354| DC Field | Value | Language |
|---|---|---|
| dc.creator | BRENDA VIANEY GIBBENS BANDALA | - |
| dc.creator | ENRIQUE MORALES AVILA | - |
| dc.creator | GUILLERMINA FERRO FLORES | - |
| dc.creator | CLARA LETICIA SANTOS CUEVAS | - |
| dc.creator | MYRNA ALEJANDRA LUNA GUTIERREZ | - |
| dc.creator | GERARDO JULIAN RAMIREZ NAVA | - |
| dc.creator | BLANCA ELI OCAMPO GARCIA | - |
| dc.date | 2019-09-27 | - |
| dc.date.accessioned | 2022-04-21T06:01:58Z | - |
| dc.date.available | 2022-04-21T06:01:58Z | - |
| dc.identifier | http://hdl.handle.net/20.500.11799/105354 | - |
| dc.identifier.uri | http://ri.uaemex.mx/handle20.500.11799/105354 | - |
| dc.description | The peptide-receptor radionuclide therapy (PRRT) is a successful approach for selectively delivering radiation within tumor sites through specific recognition of radiolabeled peptides by overexpressed receptors on cancer cell surfaces. The e cacy of PRRT could be improved by using polymeric radio- and drug- therapy nanoparticles for a concomitant therapeutic e ect on malignant cells. This research aimed to prepare and evaluate, a novel drug and radiation delivery nanosystem based on the 177Lu-labeled polyamidoamine (PAMAM) dendrimer (DN) loaded with paclitaxel (PTX) and functionalized on the surface with the Lys1Lys3(DOTA)-bombesin (BN) peptide for specific targeting to gastrin-releasing peptide receptors (GRPr) overexpressed on breast cancer cells. DN was first conjugated covalently to BN and DOTA (chemical moiety for lutetium-177 complexing) and subsequently loaded with PTX. The characterization by microscopic and spectroscopic techniques, in-vitro drug delivery tests as well as in in-vitro and in-vivo cellular uptake of 177Lu-DOTA-DN(PTX)-BN by T47D breast cancer cells (GRPr-positive), indicated the formation of an improved delivery nanosystem with target-specific recognition by GRPr. Results of the 177Lu-DOTA-DN(PTX)-BN e ect on T47D cell viability (1.3%, compared with 10.9% of 177Lu-DOTA-DN-BN and 14.0% of DOTA-DN-(PTX)-BN) demonstrated the concomitant radiotherapeutic and chemotherapeutic properties of the polymeric nanosystem as a potential agent for the treatment of GRPr-positive tumors. | - |
| dc.description | This study was supported by the grant CONACyT-CB-A1S38087 and the International Atomic Energy Agency (CRP-F2264). It was performed as part of the activities of the “Laboratorio Nacional de Investigación y Desarrollo de Radiofármacos, CONACyT”. | - |
| dc.language | eng | - |
| dc.publisher | Polymers, MDPI | - |
| dc.relation | 10.3390/polym11101572 | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | - |
| dc.source | 2073-4360 | - |
| dc.subject | polymeric nanosystems | - |
| dc.subject | dendrimers | - |
| dc.subject | radiotherapy | - |
| dc.subject | GRPr | - |
| dc.subject | paclitaxel | - |
| dc.subject | lutetium-177 | - |
| dc.subject | info:eu-repo/classification/cti/2 | - |
| dc.title | Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic E ect on Breast Cancer Cells | - |
| dc.type | article | - |
| dc.audience | students | - |
| dc.audience | researchers | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| Appears in Collections: | Producción | |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.